Clinical trials in Vandoeuvre Les Nancy – page 16

584 clinical trials in Vandoeuvre Les Nancy, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Vandoeuvre Les Nancy at a glance

584

clinical trials

Research sites2

Quick filters

584 trials in Vandoeuvre Les Nancy

Open in trial search

Gastrointestinal cancer metastatic

Recruiting

Chemotherapy Dose Adjustment for Gastrointestinal Cancer Patients with DPD Deficiency Using Fluorouracil, Capecitabine, and Oxaliplatin

Registered drugNo placebo

Chemotherapy Dose Adjustment for Gastrointestinal Cancer Patients with DPD Deficiency Using Fluorouracil, Capecitabine, and Oxaliplatin

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Unicancer

Contact Research Centre

Hepatocellular carcinoma

Recruiting

Study on Atezolizumab and Bevacizumab for Patients with Small Hepatocellular Carcinoma Undergoing Radiofrequency Ablation

Registered drugNo placebo

Study on Atezolizumab and Bevacizumab for Patients with Small Hepatocellular Carcinoma Undergoing Radiofrequency Ablation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Centre Hospitalier Universitaire De Montpellier

Contact Research Centre

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:Institut Gustave Roussy

Contact Research Centre

Adenocarcinoma gastric

Recruiting

Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

Registered drugNo placebo

Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Exl01
Sponsor:Association Gercor

Contact Research Centre

B-cell lymphoma recurrent+1

Recruiting

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Oxaliplatin
Sponsor:Miltenyi Biomedicine GmbH

Contact Research Centre

Anaplastic large cell lymphoma T- and null-cell types+3

Recruiting

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Crizotinib
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Neoplasm

Recruiting

Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

Registered drugNo placebo

Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Unicancer

Contact Research Centre

Colorectal cancer+2

Recruiting

Study on the Safety and Effects of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

Study on the Safety and Effects of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetazolamide
Sponsor:ITM Oncologics GmbH

Contact Research Centre

Glioma

Recruiting

Study Comparing Trametinib and Vinblastine for Children and Young Adults with Newly Diagnosed Low-Grade Glioma with Wild-Type BRAF Gene

Registered drugNo placebo

Study Comparing Trametinib and Vinblastine for Children and Young Adults with Newly Diagnosed Low-Grade Glioma with Wild-Type BRAF Gene

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Trametinib
Sponsor:Les Hopitaux Universitaires De Strasbourg

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy

Registered drugNo placebo

Study on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Neoplasm malignant+7

Recruiting

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Exelixis Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Vandoeuvre Les Nancy

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including head and neck squamous cell carcinoma, multiple myeloma, and prostate cancer. Studies evaluate new therapeutic approaches and diagnostic methods.

Advanced cancer treatments
Therapeutic combinations
Survival outcomes

Several trials investigate novel drug combinations and targeted therapies for improving patient outcomes.

02 Autoimmune Conditions

Comprehensive research into inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Studies explore innovative treatments including microbiota transplantation and new biological therapies.

Disease management
Treatment efficacy
Long-term outcomes

Trials aim to develop more effective maintenance therapies and improve quality of life for patients.

03 Neurological Disorders

Groundbreaking research in multiple sclerosis treatment, including both progressive and relapsing forms. Studies evaluate new therapeutic approaches and disease progression markers.

Disease modification
Treatment safety
Clinical outcomes

Focus on developing innovative treatments for better management of neurological conditions.

Back to France All countries